Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive... The introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for non-small cell lung cancer (NSCLC) with activating mutations of the EGFR has opened a new area of lung cancer treatment strategies and led to an enthusiastic search for additional mutations. Since then, numerous driver mutations such as EML4-ALK and ROS1 have been detected and specific treatment options have already been developed. However, molecular tests have to follow specific rules if applied in daily practice. The Austrian Working Group on Pulmonary Pathology and Oncology (AWGPPO) is presenting an updated version of their previous recommendation published in 2011. Several practical questions raised during the last 2 years will be addressed, such as reflex testing, selection of tissues, order of molecular tests, and the issue of resistance mechanisms. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/recommendations-of-the-austrian-working-group-on-lung-pathology-and-xFpK6aZOI9
Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0087-7
Publisher site
See Article on Publisher Site

Abstract

The introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for non-small cell lung cancer (NSCLC) with activating mutations of the EGFR has opened a new area of lung cancer treatment strategies and led to an enthusiastic search for additional mutations. Since then, numerous driver mutations such as EML4-ALK and ROS1 have been detected and specific treatment options have already been developed. However, molecular tests have to follow specific rules if applied in daily practice. The Austrian Working Group on Pulmonary Pathology and Oncology (AWGPPO) is presenting an updated version of their previous recommendation published in 2011. Several practical questions raised during the last 2 years will be addressed, such as reflex testing, selection of tissues, order of molecular tests, and the issue of resistance mechanisms.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 18, 2013

References

  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok, TS; Wu, YL; Thongprasert, S; Yang, CH; Chu, DT; Saijo, N; Sunpaweravong, P; Han, B; Margono, B; Ichinose, Y; Nishiwaki, Y; Ohe, Y; Yang, JJ; Chewaskulyong, B; Jiang, H; Duffield, EL; Watkins, CL; Armour, AA; Fukuoka, M
  • University of Hong Kong Lung Cancer Study G: the EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS
    Wong, DW-S; Leung, EL-H; So, KK-T; Tam, IY-S; Sihoe, AD-L; Cheng, L-C; Ho, K-K; Au, JS-K; Chung, L-P; Pik Wong, M
  • EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
    Inamura, K; Takeuchi, K; Togashi, Y; Nomura, K; Ninomiya, H; Okui, M; Satoh, Y; Okumura, S; Nakagawa, K; Soda, M; Choi, YL; Niki, T; Mano, H; Ishikawa, Y
  • Wong MP: a novel KIF5B-ALK variant in non-small cell lung cancer
    Wong, DW; Leung, EL; Wong, SK; Tin, VP; Sihoe, AD; Cheng, LC; Au, JS; Chung, LP
  • Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
    Weiss, J; Sos, ML; Seidel, D; Peifer, M; Zander, T; Heuckmann, JM; Ullrich, RT; Menon, R; Maier, S; Soltermann, A; Moch, H; Wagener, P; Fischer, F; Heynck, S; Koker, M; Schottle, J; Leenders, F; Gabler, F; Dabow, I; Querings, S; Heukamp, LC; Balke-Want, H; Ansen, S; Rauh, D; Baessmann, I; Altmuller, J; Wainer, Z; Conron, M; Wright, G; Russell, P; Solomon, B; Brambilla, E; Brambilla, C; Lorimier, P; Sollberg, S; Brustugun, OT; Engel-Riedel, W; Ludwig, C; Petersen, I; Sanger, J; Clement, J; Groen, H; Timens, W; Sietsma, H; Thunnissen, E; Smit, E; Heideman, D; Cappuzzo, F; Ligorio, C; Damiani, S; Hallek, M; Beroukhim, R; Pao, W; Klebl, B; Baumann, M; Buettner, R; Ernestus, K; Stoelben, E; Wolf, J; Nurnberg, P; Perner, S; Thomas, RK
  • Shibata T: KIF5B-RET fusions in lung adenocarcinoma
    Kohno, T; Ichikawa, H; Totoki, Y; Yasuda, K; Hiramoto, M; Nammo, T; Sakamoto, H; Tsuta, K; Furuta, K; Shimada, Y; Iwakawa, R; Ogiwara, H; Oike, T; Enari, M; Schetter, AJ; Okayama, H; Haugen, A; Skaug, V; Chiku, S; Yamanaka, I; Arai, Y; Watanabe, S; Sekine, I; Ogawa, S; Harris, CC; Tsuda, H; Yoshida, T; Yokota, J
  • A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC)
    Popper, H; Wrba, F; Gruber-Moesenbacher, U; Hulla, W; Pirker, R; Hilbe, W; Studnicka, M; Mohn-Staudner, A; Ploner, F
  • Histologie-basierter Algorithmus der molekularen Diagnostik des epidermalen Wachstumsfaktor-Rezeptorgens (Epidermal Growth Factor R, EGFR) beim nicht-kleinzelligen Lungenkarzinom (non-small cell lung cancer, NSCLC)—Empfehlungen der Arbeitsgruppe Pulmopathologie der Österreichischen Gesellschaft für P
    Popper, H; Wrba, F; Gruber-Mösenbacher, U; Hulla, W; Pirker, R; Hilbe, W; Studnicka, M; Mohn-Staudner, A; Ploner, F
  • Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer
    Dutt, A; Ramos, AH; Hammerman, PS; Mermel, C; Cho, J; Sharifnia, T; Chande, A; Tanaka, KE; Stransky, N; Greulich, H; Gray, NS; Meyerson, M
  • Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment
    Chen, YT; Chang, JW; Liu, HP; Yu, TF; Chiu, YT; Hsieh, JJ; Chen, YR; Wu, HD; Huang, SF
  • Effect of crizotinib on overall survival in patients with advanced non-small cell lung cancer harboring ALK gene rearrangement: a retrospective analysis
    Shaw, AT; Yeap, BY; Solomon, BJ; Riely, GJ; Gainor, J; Engelman, JA; Shapiro, GI; Costa, DB; Ou, SH; Butaney, M; Salgia, R; Maki, RG; Varella-Garcia, M; Doebele, RC; Bang, YJ; Kulig, K; Selaru, P; Tang, Y; Wilner, KD; Kwak, EL; Clark, JW; Iafrate, AJ; Camidge, DR
  • Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology
    Ou, SH; Bartlett, CH; Mino-Kenudson, M; Cui, J; Iafrate, AJ
  • Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
    Takahashi, O; Komaki, R; Smith, PD; Jurgensmeier, JM; Ryan, A; Bekele, BN; Wistuba, II; Jacoby, JJ; Korshunova, MV; Biernacka, A; Erez, B; Hosho, K; Herbst, RS; O’Reilly, MS
  • EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: analysis of data from the phase 3 FLEX study
    Pirker, R; Pereira, JR; von Pawel, J; Krzakowski, M; Ramlau, R; Park, K; de Marinis, F; Eberhardt, WE; Paz-Ares, L; Storkel, S; Schumacher, KM; von Heydebreck, A; Celik, I; O’Byrne, KJ
  • Cho BC: Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation
    Kim, SM; Kwon, OJ; Hong, YK; Kim, JH; Solca, F; Ha, SJ; Soo, RA; Christensen, JG; Lee, JH
  • New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    Oxnard, GR; Arcila, ME; Chmielecki, J; Ladanyi, M; Miller, VA; Pao, W
  • Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling
    Chaft, JE; Arcila, ME; Paik, PK; Lau, C; Riely, GJ; Pietanza, MC; Zakowski, MF; Rusch, V; Sima, CS; Ladanyi, M; Kris, MG
  • Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands
    Yano, S; Takeuchi, S; Nakagawa, T; Yamada, T
  • Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small cell lung cancer
    Kosaka, T; Yamaki, E; Mogi, A; Kuwano, H
  • A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
    Ng, KP; Hillmer, AM; Chuah, CT; Juan, WC; Ko, TK; Teo, AS; Ariyaratne, PN; Takahashi, N; Sawada, K; Fei, Y; Soh, S; Lee, WH; Huang, JW; Allen, JC; Woo, XY; Nagarajan, N; Kumar, V; Thalamuthu, A; Poh, WT; Ang, AL; Mya, HT; How, GF; Yang, LY; Koh, LP; Chowbay, B; Chang, CT; Nadarajan, VS; Chng, WJ; Than, H; Lim, LC; Goh, YT; Zhang, S; Poh, D; Tan, P; Seet, JE; Ang, MK; Chau, NM; Ng, QS; Tan, DS; Soda, M; Isobe, K; Nothen, MM; Wong, TY; Shahab, A; Ruan, X; Cacheux-Rataboul, V; Sung, WK; Tan, EH; Yatabe, Y; Mano, H; Soo, RA; Chin, TM; Lim, WT; Ruan, Y; Ong, ST
  • Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
    Katayama, R; Shaw, AT; Khan, TM; Mino-Kenudson, M; Solomon, BJ; Halmos, B; Jessop, NA; Wain, JC; Yeo, AT; Benes, C; Drew, L; Saeh, JC; Crosby, K; Sequist, LV; Iafrate, AJ; Engelman, JA
  • Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
    Doebele, RC; Pilling, AB; Aisner, DL; Kutateladze, TG; Le, AT; Weickhardt, AJ; Kondo, KL; Linderman, DJ; Heasley, LE; Franklin, WA; Varella-Garcia, M; Camidge, DR
  • Treating ALK-positive lung cancer—early successes and future challenges
    Camidge, DR; Doebele, RC
  • EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
    Thunnissen, E; Bubendorf, L; Dietel, M; Elmberger, G; Kerr, K; Lopez-Rios, F; Moch, H; Olszewski, W; Pauwels, P; Penault-Llorca, F; Rossi, G
  • Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers
    Just, PA; Cazes, A; Audebourg, A; Cessot, A; Pallier, K; Danel, C; Vacher-Lavenu, MC; Laurent-Puig, P; Terris, B; Blons, H
  • RET, ROS1 and ALK fusions in lung cancer
    Takeuchi, K; Soda, M; Togashi, Y; Suzuki, R; Sakata, S; Hatano, S; Asaka, R; Hamanaka, W; Ninomiya, H; Uehara, H; Lim Choi, Y; Satoh, Y; Okumura, S; Nakagawa, K; Mano, H; Ishikawa, Y
  • Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma
    Gu, TL; Deng, X; Huang, F; Tucker, M; Crosby, K; Rimkunas, V; Wang, Y; Deng, G; Zhu, L; Tan, Z; Hu, Y; Wu, C; Nardone, J; MacNeill, J; Ren, J; Reeves, C; Innocenti, G; Norris, B; Yuan, J; Yu, J; Haack, H; Shen, B; Peng, C; Li, H; Zhou, X; Liu, X; Rush, J; Comb, MJ